Assessment of futility in clinical trials

被引:77
作者
Snapinn, Steven [1 ]
Chen, Mon-Gy [1 ]
Jiang, Qi [1 ]
Koutsoukos, Tony [1 ]
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
关键词
conditional power; predictive power; predictive probability; sequential analysis; stochastic curtailment;
D O I
10.1002/pst.216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The term 'futility' is used to refer to the inability of a clinical trial to achieve its objectives. In particular, stopping a clinical trial when the interim results suggest that it is unlikely to achieve statistical significance can save resources that could be used on more promising research. There are various approaches that have been proposed to assess futility, including stochastic curtailment, predictive power, predictive probability, and group sequential methods. In this paper, we describe and contrast these approaches, and discuss several issues associated with futility analyses, such as ethical considerations, whether or not type I error can or should be reclaimed, one-sided vs two-sided futility rules, and the impact of futility analyses on power. Copyright (C) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:273 / 281
页数:9
相关论文
共 50 条
  • [41] Anscombe's model for sequential clinical trials revisited
    Jobjoernsson, Sebastian
    Christensen, Soeren
    SEQUENTIAL ANALYSIS-DESIGN METHODS AND APPLICATIONS, 2018, 37 (01): : 115 - 144
  • [42] Identifying and managing problematic trials: A research integrity assessment tool for randomized controlled trials in evidence synthesis
    Weibel, Stephanie
    Popp, Maria
    Reis, Stefanie
    Skoetz, Nicole
    Garner, Paul
    Sydenham, Emma
    RESEARCH SYNTHESIS METHODS, 2023, 14 (03) : 357 - 369
  • [43] CBER's Experience With Adaptive Design Clinical Trials
    Lin, Min
    Lee, Shiowjen
    Zhen, Boguang
    Scott, John
    Horne, Amelia
    Solomon, Ghideon
    Russek-Cohen, Estelle
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (02) : 195 - 203
  • [44] SEQUENTIAL-ANALYSIS OF COMPARATIVE CLINICAL-TRIALS
    BEGG, CB
    MEHTA, CR
    BIOMETRIKA, 1979, 66 (01) : 97 - 103
  • [45] Interim analysis of clinical trials based on urn models
    Zhu, Hongjian
    Hu, Feifang
    CANADIAN JOURNAL OF STATISTICS-REVUE CANADIENNE DE STATISTIQUE, 2012, 40 (03): : 550 - 568
  • [46] Adaptive Patient Population Selection Design in Clinical Trials
    Quan, Hui
    Zhou, Dongli
    Mancini, Pierre
    He, Yi
    Koch, Gary
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2012, 4 (01): : 86 - 99
  • [47] Some Thoughts on the Use of Predictive Probability in Clinical Trials
    Li, Heng
    Buzoianu, Manuela
    Chakraborty, Adrijo
    Dong, Li Ming
    Ko, Chia-Wen
    Li, Xuefeng
    Lu, Nelson
    Qu, Yanping
    Xu, Yunling
    Yan, Xu
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (03) : 464 - 466
  • [48] Challenges in Implementing Futility Schemes, with Reference to Aducanumab
    Paul Gallo
    Satrajit Roychoudhury
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 515 - 520
  • [49] Some Thoughts on the Use of Predictive Probability in Clinical Trials
    Heng Li
    Manuela Buzoianu
    Adrijo Chakraborty
    Li Ming Dong
    Chia-Wen Ko
    Xuefeng Li
    Nelson Lu
    Yanping Qu
    Yunling Xu
    Xu Yan
    Therapeutic Innovation & Regulatory Science, 2023, 57 : 464 - 466
  • [50] Predictive checking for Bayesian interim analyses in clinical trials
    Daimon, Takashi
    CONTEMPORARY CLINICAL TRIALS, 2008, 29 (05) : 740 - 750